Physical frailty and sarcopenia (PF&S) recapitulates all the hallmarks of aging and has become a focus in geroscience. Factors spanning muscle-specific processes (e.g., mitochondrial dysfunction in skeletal myocytes) to systemic changes (e.g., inflammation and amino acid dysmetabolism) have been pinpointed as possible contributors to PF&S pathophysiology. However, the search for PF&S biomarkers allowing the early identification and tracking of the condition over time is ongoing. This is mainly due to the phenotypic heterogeneity of PF&S, its unclear pathophysiology, and the frequent superimposition of other age-related conditions. Hence, presently, the identification of PF&S relies upon clinical, functional, and imaging parameters. The adoption of multi-marker approaches (combined with multivariate modeling) has shown great potential for addressing the complexity of PF&S pathophysiology and identifying candidate biological markers. Well-designed longitudinal studies are necessary for the incorporation of reliable biomarkers into clinical practice and for unveiling novel targets that are amenable to interventions.

Picca, A., Calvani, R., Cesari, M., Landi, F., Bernabei, R., Coelho-Junior, H. J., Marzetti, E., Biomarkers of physical frailty and sarcopenia: Coming up to the place?, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2020; 21 (16): 1-16. [doi:10.3390/ijms21165635] [http://hdl.handle.net/10807/164714]

Biomarkers of physical frailty and sarcopenia: Coming up to the place?

Calvani, R.
;
Cesari, M.;Landi, F.;Bernabei, R.;Marzetti, E.
2020

Abstract

Physical frailty and sarcopenia (PF&S) recapitulates all the hallmarks of aging and has become a focus in geroscience. Factors spanning muscle-specific processes (e.g., mitochondrial dysfunction in skeletal myocytes) to systemic changes (e.g., inflammation and amino acid dysmetabolism) have been pinpointed as possible contributors to PF&S pathophysiology. However, the search for PF&S biomarkers allowing the early identification and tracking of the condition over time is ongoing. This is mainly due to the phenotypic heterogeneity of PF&S, its unclear pathophysiology, and the frequent superimposition of other age-related conditions. Hence, presently, the identification of PF&S relies upon clinical, functional, and imaging parameters. The adoption of multi-marker approaches (combined with multivariate modeling) has shown great potential for addressing the complexity of PF&S pathophysiology and identifying candidate biological markers. Well-designed longitudinal studies are necessary for the incorporation of reliable biomarkers into clinical practice and for unveiling novel targets that are amenable to interventions.
Inglese
Picca, A., Calvani, R., Cesari, M., Landi, F., Bernabei, R., Coelho-Junior, H. J., Marzetti, E., Biomarkers of physical frailty and sarcopenia: Coming up to the place?, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2020; 21 (16): 1-16. [doi:10.3390/ijms21165635] [http://hdl.handle.net/10807/164714]
File in questo prodotto:
File Dimensione Formato  
IntJMolSci2020b.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 773.02 kB
Formato Adobe PDF
773.02 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/164714
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 22
social impact